BI 224436

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
BI 224436
BI 224436.svg
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life7 hrs (simulated)[1]
CAS Number
PubChem CID
Chemical and physical data
Molar mass442.515 g/mol g·mol−1
3D model (JSmol)

BI 224436 was an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in its mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]

Clinical trials were abandoned in advance of Phase 1.[5]